

REMARKS

Claims 1-66 are pending in this application and presented for examination. Applicants acknowledge the renumbering of claims 37-59 to claims 44-66 respectively. Claims 46, 53 and 62 have been amended. No new matter has been introduced with the foregoing amendments. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made." Reconsideration is respectfully requested.

I. Support for Amendments

Support for the amendments to claims 46, 53, and 62 is found throughout the specification as originally filed. More particularly, support is found, for example, in claims 21-24. No new matter has been introduced with the foregoing amendments. As such, Applicants respectfully request that the amendments be entered.

II. Response to the Restriction Requirement

The Examiner has indicated that restriction to one of the following inventions is required under 35 U.S.C. 121:

Group I. Claims 1-43, drawn to a compound represented by the formula A-L-D, wherein, A is an anchoring moiety that is specific for first target sit on a protein, L is a linking group, and D is a drug that is specific for a second target site on the protein, and a method for the localization of a drug at a preselected target site comprising administering to a host a compound of A-L-D; or

Group II. Claims 44-66, drawn to a method for identifying a drug that binds at a preselected target site on a biological molecule comprising providing the preselected target site having a chemically reactive group, contacting the biological target

molecule with a drug having an anchoring moiety specific for the chemically reactive group, and identifying the drug having the anchoring moiety.

In response, Applicants hereby elect Group II, with traverse. Claims readable thereon include claims 44-66. Applicants assert that unity of invention exists among claims 1-66. Unity of invention exists when there is a technical relationship among the claimed inventions involving one or more special technical features. The term "special technical feature" is defined as meaning those technical features that define a contribution which each of the inventions considered as a whole, makes over the prior art. The determination is made based on the contents of the claims as interpreted in light of the description and drawings. The claims herein recite various methods of identifying drugs that bind to preselected selected targets sites and the drug themselves. Therefore, unity of invention exists.

Upon the Examiner's request, Applicants select "a local anesthetic" such as benzocaine with regard to one drug in claims 46, 53 and 62. Other examples of local anesthetics include lidocaine, dibucaine and chlorpromazine. With regard to one protein of claims 48, 55 and 64, Applicants select a sodium channel. With regard to one anchoring moiety of claims 49-50, 56-57 and 65-66, Applicants select a sulfhydryl reactive group, such as a methanethiosulfonyl group.

Applicants respectfully direct the Examiner's attention to Example 1 for example, wherein a benzocaine derivative (p-aminobenzoic acid) is reacted with a methansulfonate (2-hydroxyethyl methansulfonate) to produce a sulfhydryl reactive group.


III. CONCLUSION

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. In view of the foregoing, Applicants respectfully request early action on the merits.

Applicants believe no fee is required. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,



Joseph R. Snyder
Reg. No. 39,381

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
JS
WC 9036290 v1

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Please amend the claims 46, 53 and 62 as follows:

1 **46.** (Amended) The method in accordance with claim **44**, wherein said
2 drug is a member of the group consisting of a peptide, a peptoid, a random bio-oligomer,
3 a benzodiazepine, a hydantoin, a dipeptide, a vinylogous polypeptide, a nonpeptidal
4 peptidomimetic, an oligocarbamate, a peptidyl phosphonate, a nucleic acid, an antibody,
5 an isoprenoid, a thiazolidinone, a metathiazanone, a pyrrolidine, a morpholino
6 compound, [and] a cyclopentane carboxylic acid, phenylalkylamines, dihydropyridines,
7 an antineoplastic agent and a local anesthetic.

1 **53.** (Amended) The method in accordance with claim **52**, wherein said
2 drug is a member of the group consisting of a peptide, a peptoid, a random bio-oligomer,
3 a benzodiazepine, a hydantoin, a dipeptide, a vinylogous polypeptide, a nonpeptidal
4 peptidomimetic, an oligocarbamate, a peptidyl phosphonate, a nucleic acid, an antibody,
5 an isoprenoid, a thiazolidinone, a metathiazanone, a pyrrolidine, a morpholino
6 compound, [and] a cyclopentane carboxylic acid, phenylalkylamines, dihydropyridines,
7 an antineoplastic agent and a local anesthetic.

1 **62.** (Amended) The method in accordance with claim **59**, wherein said
2 first drug is a member of the group consisting of a peptide, a peptoid, a random bio-
3 oligomer, a benzodiazepine, a hydantoin, a dipeptide, a vinylogous polypeptide, a
4 nonpeptidal peptidomimetic, an oligocarbamate, a peptidyl phosphonate, a nucleic acid,
5 an antibody, an isoprenoid, a thiazolidinone, a metathiazanone, a pyrrolidine, a
6 morpholino compound, cyclopentane carboxylic acid, phenylalkylamines, [and]
7 dihydropyridines, an antineoplastic agent and a local anesthetic.